Barriers and perceived usefulness of an ECHO intervention for office-based buprenorphine treatment for opioid use disorder in North Carolina: A qualitative study

被引:29
|
作者
Shea, Christopher M. [1 ]
Gertner, Alex K. [1 ]
Green, Sherri L. [1 ]
机构
[1] Univ N Carolina, Chapel Hill, NC 27599 USA
关键词
Primary health care; medication assisted treatment; opioid use disorder; ECHO; implementation barriers; PROJECT ECHO; SPECIALISTS; ADDICTION; CAPACITY; CARE;
D O I
10.1080/08897077.2019.1694617
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: Medication treatment for opioid use disorder (M-OUD) is underutilized, despite research demonstrating its effectiveness in treating opioid use disorder (OUD). The UNC Extension for Community Healthcare Outcomes for Rural Primary Care Medication Assisted Treatment (UNC ECHO for MAT) project was designed to evaluate interventions for reducing barriers to delivery of M-OUD by rural primary care providers in North Carolina. A key element was tele-conferenced sessions based on the University of New Mexico Project ECHO model, comprised of case discussions and didactic presentations using a "hub and spoke" model, with expert team members at the hub site and community-based providers participating from their offices (i.e., spoke sites). Although federal funders have promoted use of the model, barriers for providers to participate in ECHO sessions are not well documented. Methods: UNC ECHO for MAT included ECHO sessions, provider-to-provider consultations, and practice coaching. We conducted 20 semi-structured interviews to assess perceived usefulness of the UNC ECHO for MAT intervention, barriers to participation in the intervention, and persistent barriers to prescribing M-OUD. Results: Participants were generally satisfied with ECHO sessions and provider-to-provider consultations; however, perceived value of practice support was less clear. Primary barriers to participating in ECHO sessions were timing and length of sessions. Participants recommended recording ECHO sessions for viewing later, and some thought incentives for either the practice or provider could facilitate participation. Providers who had participated in ECHO sessions valued the expertise on the expert team; the team's ability to develop a supportive, collegial environment; and the value of a community of providers interested in learning from each other, particularly through case discussions. Conclusions: Despite the perceived value of ECHO, barriers may prevent consistent participation. Also, barriers to M-OUD delivery remain, including some that ECHO alone cannot address, such as Medicaid and private-insurer policies and availability of psychosocial resources.
引用
收藏
页码:54 / 64
页数:11
相关论文
共 50 条
  • [31] The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment?
    Sullivan, LE
    Chawarski, M
    O'Connor, PG
    Schottenfeld, RS
    Fiellin, DA
    DRUG AND ALCOHOL DEPENDENCE, 2005, 79 (01) : 113 - 116
  • [32] Feasibility of Implementing Shared Medical Appointments (SMAs) for Office-Based Opioid Treatment With Buprenorphine: A Pilot Study
    Suzuki, Joji
    Zinser, Jennifer
    Klaiber, Brenda
    Hannon, Melanie
    Grassi, Hope
    Spinosa, Madeline
    Ramirez, Altagracia
    Issa, Mohammed
    Feman, Siu Ping Chin
    SUBSTANCE ABUSE, 2015, 36 (02) : 166 - 169
  • [33] Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians
    Arfken, Cynthia L.
    Johanson, Chris-Ellyn
    di Menza, Salvatore
    Schuster, Charles Roberts
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2010, 39 (02) : 96 - 104
  • [34] Training in Buprenorphine and Office-Based Opioid Treatment: A Survey of Psychiatry Residency Training Programs
    Suzuki, Joji
    Ellison, Tatyana V.
    Connery, Hilary S.
    Surber, Charles
    Renner, John A.
    ACADEMIC PSYCHIATRY, 2016, 40 (03) : 498 - 502
  • [35] A pilot study of mindful body awareness training as an adjunct to office-based medication treatment of opioid use disorder
    Price, Cynthia J.
    Merrill, Joseph O.
    McCarty, Rachelle L.
    Pike, Kenneth C.
    Tsui, Judith I.
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2020, 108 : 123 - 128
  • [36] Statement of the American Society of Addiction Medicine Consensus Panel on the Use of Buprenorphine in Office-Based Treatment of Opioid Addiction
    Kraus, Mark L.
    Alford, Daniel P.
    Kotz, Margaret M.
    Levounis, Petros
    Mandell, Todd W.
    Meyer, Marjorie
    Salsitz, Edwin A.
    Wetterau, Norman
    Wyatt, Stephen A.
    JOURNAL OF ADDICTION MEDICINE, 2011, 5 (04) : 254 - 263
  • [37] Office-based Methadone Prescribing for Opioid Use Disorder: The Canadian Model
    Kleinman, Robert A.
    Brothers, Thomas D.
    Danilewitz, Marlon
    Bahji, Anees
    JOURNAL OF ADDICTION MEDICINE, 2022, 16 (05) : 499 - 504
  • [38] A collaborative opioid prescribing (CoOP) model linking opioid treatment programs with office-based buprenorphine providers
    Kenneth B Stoller
    Addiction Science & Clinical Practice, 10 (Suppl 1)
  • [39] Buprenorphine Induction: A Major Barrier for Physician Adoption of Office-Based Opioid Dependence Treatment
    Gunderson, Erik W.
    JOURNAL OF ADDICTION MEDICINE, 2011, 5 (04) : 304 - 305
  • [40] Training in Buprenorphine and Office-Based Opioid Treatment: A Survey of Psychiatry Residency Training Programs
    Joji Suzuki
    Tatyana V. Ellison
    Hilary S. Connery
    Charles Surber
    John A. Renner
    Academic Psychiatry, 2016, 40 : 498 - 502